| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant therapy for stage II melanoma: the need for further studies
|
Lee, Rebecca
|
|
|
189 |
C |
p.
|
article
|
| 2 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
|
Boccaccino, Alessandra
|
|
|
189 |
C |
p.
|
article
|
| 3 |
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
|
Rossi, Alessandro
|
|
|
189 |
C |
p.
|
article
|
| 4 |
Cancer in conflict: The impact of the war in Ukraine on Moldova
|
Vulpe, Horia
|
|
|
189 |
C |
p.
|
article
|
| 5 |
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study
|
Bachet, Jean-Baptiste
|
|
|
189 |
C |
p.
|
article
|
| 6 |
Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials
|
Fountzilas, Elena
|
|
|
189 |
C |
p.
|
article
|
| 7 |
Early phase clinical trials in oncology: Realising the potential of seamless designs
|
Jaki, Thomas
|
|
|
189 |
C |
p.
|
article
|
| 8 |
Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool
|
Leone, José P.
|
|
|
189 |
C |
p.
|
article
|
| 9 |
External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes
|
Li, Andrew T.
|
|
|
189 |
C |
p.
|
article
|
| 10 |
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition
|
Ferguson, Robert
|
|
|
189 |
C |
p.
|
article
|
| 11 |
Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group
|
Massi, Daniela
|
|
|
189 |
C |
p.
|
article
|
| 12 |
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies
|
Rubinstein, Samuel M.
|
|
|
189 |
C |
p.
|
article
|
| 13 |
Letter Re: Oral cavity adjuvant therapy—a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity
|
Kahvecioglu, Alper
|
|
|
189 |
C |
p.
|
article
|
| 14 |
Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)
|
Soussain, Carole
|
|
|
189 |
C |
p.
|
article
|
| 15 |
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
|
Hertler, Caroline
|
|
|
189 |
C |
p.
|
article
|
| 16 |
Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy
|
Jia, Keren
|
|
|
189 |
C |
p.
|
article
|
| 17 |
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE
|
Hescot, Ségolène
|
|
|
189 |
C |
p.
|
article
|
| 18 |
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)
|
Shaib, Walid L.
|
|
|
189 |
C |
p.
|
article
|
| 19 |
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
|
Kennedy, Oliver John
|
|
|
189 |
C |
p.
|
article
|
| 20 |
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
|
González-Martín, Antonio
|
|
|
189 |
C |
p.
|
article
|
| 21 |
Publisher's Note
|
|
|
|
189 |
C |
p.
|
article
|
| 22 |
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort
|
Grinda, Thomas
|
|
|
189 |
C |
p.
|
article
|
| 23 |
Recognising the health dividend of peace: cancer and Northern Ireland
|
Lawler, M.
|
|
|
189 |
C |
p.
|
article
|
| 24 |
Response to letter entitled: Re: Oral cavity adjuvant therapy (OCAT) - a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity
|
Ghosh-Laskar, Sarbani
|
|
|
189 |
C |
p.
|
article
|
| 25 |
Response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France
|
Hill, Catherine
|
|
|
189 |
C |
p.
|
article
|
| 26 |
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
|
Persano, Mara
|
|
|
189 |
C |
p.
|
article
|
| 27 |
Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis
|
Chavaz, L.
|
|
|
189 |
C |
p.
|
article
|
| 28 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea
|
Park, Byung Kyu
|
|
|
189 |
C |
p.
|
article
|
| 29 |
Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer
|
Han, Ruoshuang
|
|
|
189 |
C |
p.
|
article
|
Journal description